Research location
Azusa
California, United States
Advertisement
Research activity in Azusa
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 13 trials and 15 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Azusa
13 linked trials · page 1 of 1A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye DiseaseNCT04391894 · 2020-10-06 · 1 site observation
COMPLETED
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular HypertensionNCT03310580 · 2017-11-15 · 1 site observation
COMPLETED
Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's SyndromeNCT03226444 · 2017-06-30 · 1 site observation
COMPLETED
Bexagliflozin Efficacy and Safety TrialNCT02558296 · 2015-10-01 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney DiseaseNCT02177786 · 2014-06-01 · 1 site observation
COMPLETED
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt NephropathyNCT01712061 · 2012-12-01 · 1 site observation
COMPLETED
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)NCT01621178 · 2012-07-01 · 1 site observation
COMPLETED
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With NephropathyNCT01399580 · 2011-08-01 · 2 site observations
COMPLETED
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) InhibitorNCT01356849 · 2011-04-01 · 1 site observation
COMPLETED
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt NephropathyNCT01200394 · 2010-12-01 · 2 site observations
COMPLETED
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System InhibitorsNCT00920764 · 2009-06-01 · 1 site observation
COMPLETED
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLCNCT00828841 · 2008-12-01 · 1 site observation
COMPLETED
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenNCT00346216 · 2006-10-04 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.